This study is looking at using two drugs, *brentuximab vedotin* and *nivolumab*, to treat a type of cancer called classic Hodgkin lymphoma. Hodgkin lymphoma is a cancer of the lymphatic system, which is part of the immune system. Some people’s cancer comes back (this is called *relapsed*) or doesn’t respond to treatment (*refractory*). Brentuximab vedotin is a special type of medicine called a monoclonal antibody that targets cancer cells and delivers a toxic agent to kill them. Nivolumab is another monoclonal antibody that helps the immune system fight cancer.

The study aims to see how well these two drugs work together in patients who have already tried them separately with other treatments. If you join this study, you will receive both drugs through an IV every 21 days, for up to 16 cycles. The doctors will check on you 30 days after the study ends, then every 3 months for 2 years, and every 6 months for 3 years.

• Duration: Treatment cycles every 21 days, for up to 16 cycles.
• Eligibility: Must be 12 years or older with specific previous treatments.
• Follow-Up: Regular check-ups for up to 5 years after treatment.